Urinary stones in HIV-1-positive patients treated with indinavir [3]

Lancet

Volumn 349, Issue 9061, 1997, Pages 1294-1295

  Daudon, M ^a   Estepa L ^a   Viard, J P ^a   Joly, D ^a   Jungers, P ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR;

ADULT; CHEMICAL ANALYSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFRARED SPECTROMETRY; KIDNEY COLIC; LETTER; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; UROLITHIASIS;

EID: 0343471516     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)62506-8     Document Type: Article

References (5)

1. Nelson H. Protease inhibitors show promise in HIV infection. Lancet 1996; 347: 383.
2. R-Indinavir".
3. Daudon M, Bader CA, Jungers P. Urinary Calculi: Review of classification methods and correlations with etiology. Scanning Microsc 1993; 7: 1081-106.
4. Balani SH, Arisen BH, Mathai L, et al. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab Deposition 1995; 23: 266-70.
5. Chen IW, Vastag KJ, Lin JH. High-performance liquid chromatographic determination of a potent and selective HIV protease inhibitor (L-735,524) in rat, dog and monkey plasma. J Chromatography B 1995; 672: 111-17.